Article
Gastroenterology & Hepatology
Tomomi Kogiso, Takaomi Sagawa, Kazuhisa Kodama, Makiko Taniai, Etsuko Hashimoto, Katsutoshi Tokushige
Summary: The study on 314 Japanese NAFLD patients found that ALDH2 gene SNP may affect the prognosis of NAFLD, and patients carrying the risk genes PNPLA3 (GG) and ALDH2 (non-GG) have a poorer prognosis. Subgroup analysis revealed that the disease status and genotypes of some patients were associated with prognosis.
ANNALS OF HEPATOLOGY
(2021)
Article
Microbiology
Emma Pietsch, Abhinay Ramaprasad, Sabrina Bielfeld, Yvonne Wohlfarter, Bohumil Maco, Korbinian Niedermueller, Louisa Wilcke, Joachim Kloehn, Markus A. Keller, Dominique Soldati-Favre, Michael J. Blackman, Tim-Wolf Gilberger, Paul-Christian Burda
Summary: Malaria parasites rely on a functional electron transport chain (ETC) within their mitochondrion for proliferation, making it a target for antimalarial drugs. This study identifies a patatin-like phospholipase, PfPNPLA2, as important for parasite replication and mitochondrial function in Plasmodium falciparum. Parasites lacking PfPNPLA2 show defects in their ETC and become hypersensitive to mitochondrion-targeting drugs. Furthermore, PfPNPLA2-deficient parasites exhibit differences in the composition of their cardiolipins, a unique class of phospholipids with crucial roles in mitochondrial functions. The study also demonstrates that parasites devoid of PfPNPLA2 have a defect in gametocyte maturation, highlighting the significance of a functional ETC for parasite transmission.
Article
Oncology
Tomomi Kogiso, Yuri Ogasawara, Kentaro Horiuchi, Makiko Taniai, Katsutoshi Tokushige
Summary: This study examined the association between HSD17B13 gene polymorphisms and the characteristics of Japanese fatty liver disease (FLD) patients. Patients with the HSD17B13 A/A genotype had a higher incidence of hepatocellular carcinoma, cardiovascular diseases, and hypertension. Patients without the HSD17B13 A/A genotype had more severe steatosis. Combining SNP profiles with other risk factors can be beneficial in screening FLD-HCC.
Review
Gastroenterology & Hepatology
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with a significant global health burden. Non-invasive tests for assessing and monitoring NAFLD are now feasible and highlighted in international guidelines. Identifying high-risk populations and utilizing various screening methods are important for precise and effective screening strategies.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Wenqian Lu, Cheng Hu
Summary: This review summarizes recent studies on biomolecules associated with GDM and postpartum diabetes, focusing on their predictive value in screening and diagnosis.
CHINESE MEDICAL JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Sylwia Ziolkowska, Marcin Kosmalski, Lukasz Kolodziej, Aleksandra Jablkowska, Janusz Zbigniew Szemraj, Tadeusz Pietras, Maciej Jablkowski, Piotr Lech Czarny
Summary: Oxidative stress is crucial in the development of NAFLD and can cause DNA damage. The study examined the relationship between different genetic variants of BER-associated genes and the risk of NAFLD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Health Care Sciences & Services
Jungeun Shin, Soo Jung Choi, Han Rim Lee, Kyungdo Han, Jiwon Chang, Su-Min Jeong, Yun-sun Choi, Daeho Lee, Dong Wook Shin
Summary: This study found that the association between NAFLD and DM was stronger in pre-menopausal women than in post-menopausal women. This might be due to the protective effect of estrogen, which is possibly in higher production in the peripheral fat tissue of post-menopausal women with NAFLD.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Endocrinology & Metabolism
Yumeng Tian, Ping Li
Summary: This article reviews the research progress in the use of genetic risk score (GRS) in diabetes mellitus in recent years and discusses future prospects.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Jinhan Zhao, Xiaoyi Xu, Xinhuan Wei, Shuang Zhang, Hangfei Xu, Xiaodie Wei, Yang Zhang, Jing Zhang
Summary: This study identified a significant correlation between SAMM50 genetic polymorphism and NAFLD in the elderly, contributing to a better understanding of the impact of age and genetics on this condition. Additionally, it provides a potential predictive model for early clinical warning of NAFLD.
Review
Endocrinology & Metabolism
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo
Summary: This meta-analysis examined the efficacy of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Results showed significant improvements in hepatic fat content, liver biochemistry, body composition, glucose parameters, lipid parameters, insulin sensitivity, and inflammatory markers following treatment with glucagon-like peptide-1 receptor agonists. Glucagon-like peptide-1 receptor agonists were also found to significantly decrease hepatic fat content compared to other treatments, showing promise in improving both diabetes and non-alcoholic fatty liver disease phenotype.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Gastroenterology & Hepatology
Elina En Li Cho, Chong Zhe Ang, Jingxuan Quek, Clarissa Elysia Fu, Lincoln Kai En Lim, Zane En Qi Heng, Darren Jun Hao Tan, Wen Hui Lim, Jie Ning Yong, Rebecca Zeng, Douglas Chee, Benjamin Nah, Cosmas Rinaldi Adithya Lesmana, Aung Hlaing Bwa, Khin Maung Win, Claire Faulkner, Majd B. Aboona, Mei Chin Lim, Nicholas Syn, Anand V. V. Kulkarni, Hiroyuki Suzuki, Hirokazu Takahashi, Nobuharu Tamaki, Karn Wijarnpreecha, Daniel Q. Q. Huang, Mark Muthiah, Cheng Han Ng, Rohit Loomba
Summary: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. This study determined a high prevalence of NAFLD, non-alcoholic steatohepatitis (NASH), and fibrosis in people with T2DM.
Article
Pediatrics
Kyung Jae Lee, Jin Soo Moon, Nan Young Kim, Jae Sung Ko
Summary: The study found that genetic variants of PNPLA3, TM6SF2, and SAMM50 are associated with the development and severity of pediatric NAFLD, with a greater impact in children with overweight. These four genetic variants have synergistic effects on the severity of pediatric NAFLD.
Article
Nutrition & Dietetics
Hui-Ju Tsai, Wei-Chun Hung, Wei-Wen Hung, Yen-Jung Lee, Yo-Chia Chen, Chun-Ying Lee, Yi-Chun Tsai, Chia-Yen Dai
Summary: This study aimed to explore the association between short-chain fatty acids (SCFAs) and the severity of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2D) patients. The results showed that the circulating levels of isobutyrate and methylbutyrate were negatively correlated with NAFLD severity. This suggests that SCFAs may be related to the severity of NAFLD in T2D patients.
Article
Medicine, Research & Experimental
Poliana C. Marinello, Paola S. Cella, Mayra T. J. Testa, Phillipe B. Guirro, Walison Augusto da Silva Brito, Camila S. Padilha, Alessandra L. Cecchini, Robin P. da Silva, Jose Alberto R. Duarte, Rafael Deminice
Summary: This study investigated the effects of creatine supplementation on the pathogenesis of non-alcoholic fatty liver disease and alcoholic liver disease. The results showed that creatine supplementation prevented high-fat diet-induced non-alcoholic fatty liver disease but exacerbated ethanol-induced alcoholic liver disease. The exacerbating effects may be related to oxidative stress and inflammation-mediated upregulation of ethanol metabolism.
Review
Medicine, General & Internal
Elizabeth E. Powell, Vincent Wai-Sun Wong, Mary Rinella
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common global health issue with significant associations with metabolic syndrome and type 2 diabetes, leading to serious complications like cirrhosis and hepatocellular carcinoma. While cardiovascular disease and extrahepatic malignancy are the main causes of death in NAFLD patients, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality.
Article
Surgery
Naruhiko Honmyo, Tsuyoshi Kobayashi, Shintaro Kuroda, Kentaro Ide, Masahiro Ohira, Hiroyuki Tahara, Hiroshi Morimoto, Naoki Tanimine, Michinori Hamaoka, Megumi Yamaguchi, Masateru Yamamoto, Daisuke Takei, Hiroshi Aikata, Kazuaki Chayama, Hideki Ohdan
Summary: This study identified risk factors for hepatocellular carcinoma (HCC) development after splenectomy for portal hypertension. The etiology of cirrhosis, presence of HCC history, and preoperative hemoglobin level were found to be associated with HCC development. The predictive model constructed in this study may assist in surveillance for HCC after splenectomy in patients with portal hypertension.
Review
Gastroenterology & Hepatology
C. Nelson Hayes, Michio Imamura, Junko Tanaka, Kazuaki Chayama
Summary: Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but most patients can now expect to achieve a sustained virological response (SVR). Adverse events are rare or mild, and patients with compensated cirrhosis and other co-morbidities are often eligible for treatment. However, a small number of patients fail to eradicate the virus even after retreatment.
LIVER INTERNATIONAL
(2022)
Article
Multidisciplinary Sciences
Kenji Yamaoka, Kenichiro Kodama, Tomokazu Kawaoka, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Ryoichi Miura, Shigeki Yano, Serami Murakami, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Michio Imamura, Shoichi Takahashi, Akiko Nagao, Kazuaki Chayama, Hiroshi Aikata
Summary: The study found that assessing body composition before and after lenvatinib treatment using BIA can be useful in predicting prognosis in patients with hepatocellular carcinoma.
Article
Endocrinology & Metabolism
Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Yukiko Nakano, Masato Kajikawa, Kenichi Yoshimura, Gaku Aoki, Kazuaki Chayama, Chikara Goto, Aya Mizobuchi, Yiming Han, Farina Mohamad Yusoff, Shinji Kishimoto, Tatsuya Maruhashi, Ayumu Nakashima, Yukihito Higashi
Summary: This study investigated the relationship between HbA1c levels and vascular function in patients with type 2 diabetes mellitus receiving antidiabetic drug treatment. Results showed an inverted U-shaped association between HbA1c levels and FMD, with both low (<6.5%) and high (>= 8.0%) HbA1c levels associated with endothelial dysfunction, while vascular smooth muscle function was similar regardless of HbA1c levels.
JOURNAL OF DIABETES INVESTIGATION
(2022)
Article
Gastroenterology & Hepatology
Suguru Kurokawa, Masato Yoneda, Yuji Ogawa, Yasushi Honda, Takaomi Kessoku, Kento Imajo, Satoru Saito, Atsushi Nakajima, Kikuko Hotta
Summary: In this study, two differentially methylated region networks were examined in viral hepatitis and hepatocellular carcinoma. One network was associated with fibrosis and tumorigenesis in both NAFLD and viral hepatitis, while the other network was specifically associated with NAFLD progression. FABP1, SGK2, and HNF4A were identified as potential candidate targets for the prevention and treatment of HCC.
BMC GASTROENTEROLOGY
(2022)
Article
Immunology
Yosuke Suehiro, Masataka Tsuge, Mio Kurihara, Takuro Uchida, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Grace Naswa Makokha, Takashi Nakahara, Eisuke Murakami, Hiromi Abe-Chayama, Tomokazu Kawaoka, Daiki Miki, Michio Imamura, Hiroshi Aikata, C. Nelson Hayes, Takashi Fujita, Kazuaki Chayama
Summary: HBV infection upregulates TRAIL-R3, which inhibits both TRAIL-dependent apoptosis and suppression of HBV replication. The upregulation of TRAIL-R3 is regulated by the TRAIL-R3 promoter and HBV signal pathway. The results suggest a mechanism by which HBV persists by escaping host immunity through upregulation of TRAIL-R3.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Jeong Heo, Hiromitsu Kumada, Fumitaka Suzuki, Yoshiyuki Suzuki, Qing Xie, Jidong Jia, Yoshiyasu Karino, Jinlin Hou, Kazuaki Chayama, Michio Imamura, Judy Y. Lao-Tan, Seng Gee Lim, Yasuhito Tanaka, Wen Xie, Jung-Hwan Yoon, Zhongping Duan, Masayuki Kurosaki, Sung-Jae Park, Madalinee Eternity Labio, Rajneesh Kumar, Young-Oh Kweon, Hyung Joon Yim, Yu Tao, Jennifer Cremer, Robert Elston, Matt Davies, Sharon Baptiste-Brown, Kelong Han, Fiona M. Campbell, Melanie Paff, Dickens Theodore
Summary: This study evaluated the safety and efficacy of GSK3389404, a drug targeting chronic HBV infection. The results showed that GSK3389404 can reduce the production of HBV viral proteins, although no optimal dosing regimen was identified.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yuki Shirane, Eisuke Murakami, Michio Imamura, Masanari Kosaka, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Daiki Miki, Masami Yamauchi, Wataru Okamoto, Masataka Tsuge, Keigo Chosa, Kazuo Awai, Hiroshi Aikata, Shiro Oka
Summary: This study aimed to investigate the clinical significance of HVPG, subsequent EVs exacerbation, and prognosis in patients with GV treated with BRTO. It was found that HVPG increases after BRTO, and post-HVPG has a higher predictive ability for EVs exacerbation than pre-HVPG. In addition, liver stiffness measurement is a potential prognostic parameter in patients who undergo BRTO.
BMC GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Osamu Yoshida, Sheikh Mohammad Fazle Akbar, Yusuke Imai, Takahiro Sanada, Kyoko Tsukiyama-Kohara, Takashi Miyazaki, Taizou Kamishita, Teruki Miyake, Yoshio Tokumoto, Hayato Hikita, Masataka Tsuge, Masahito Shimizu, Mamun Al Mahtab, Julio Cesar Aguilar, Gerardo Guillen, Michinori Kohara, Yoichi Hiasa
Summary: This study investigated the safety and efficacy of CVP-NASVAC in treating patients with chronic hepatitis B (CHB). The results showed that CVP-NASVAC induced anti-HBs antibodies and reduced HBsAg levels in some patients, leading to functional cure in 9.5% of the participants.
HEPATOLOGY RESEARCH
(2023)
Editorial Material
Gastroenterology & Hepatology
Masataka Tsuge, Tomokazu Kawaoka, Shiro Oka
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Yosuke Suehiro, Takuro Uchida, Masataka Tsuge, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Michio Imamura, Hiroshi Aikata, Koji Arihiro, Shiro Oka
Summary: We present the case of a rare occurrence of acute liver injury in a patient with non-alcoholic fatty liver disease (NAFLD) due to daily exposure to small amounts of chloroform. The patient had been regularly monitored and showed stable alanine aminotransferase (ALT) levels until a sudden increase in late August 2014. The liver injury was attributed to chloroform exposure and was successfully treated with the administration of 600 mg/day of ursodeoxycholic acid.
CLINICAL JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Takahiro Kinami, Kei Amioka, Tomokazu Kawaoka, Shinsuke Uchikawa, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Yasutoshi Fujii, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka
Summary: This study investigated the relationship between radiological response and prognosis in HCC patients to determine whether to continue Atezo + Beva treatment. The results showed that a decrease in AFP level may reflect early efficacy and AFP trends can help decide the treatment strategy. It was found that a 25% or greater increase in AFP value was associated with disease progression and a decrease in AFP was related to improved progression-free survival.
Article
Gastroenterology & Hepatology
Yusuke Johira, Takashi Nakahara, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, C. Nelson Hayes, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka
Summary: This study investigated the clinical characteristics of MAFLD-HCC patients compared with NAFLD-HCC patients and considered the validity and challenges of the new criteria. The majority of non-B, non-C HCC cases with hepatic steatosis were attributed to MAFLD. Further examination and revision of the criteria are needed to select fatty liver patients at high risk of developing HCC efficiently.
BMC GASTROENTEROLOGY
(2023)
Article
Oncology
Yosuke Tamura, Atsushi Ono, Hikaru Nakahara, Clair Nelson Hayes, Yasutoshi Fujii, Peiyi Zhang, Masami Yamauchi, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Masahiro Serikawa, Daiki Miki, Tomokazu Kawaoka, Wataru Okamoto, Michio Imamura, Yuko Nakamura, Kazuo Awai, Tsuyoshi Kobayashi, Hideki Ohdan, Masashi Fujita, Hidewaki Nakagawa, Kazuaki Chayama, Hiroshi Aikata, Shiro Oka
Summary: High-intensity Gd-EOB-DTPA-enhanced MRI imaging (EOB-MRI) in the hepatobiliary phase (HB) can predict the immune microenvironment and molecular subtype in hepatocellular carcinoma (HCC) patients but not the response to atezolizumab + bevacizumab therapy. The high-intensity group benefits from bevacizumab, while the low-intensity group benefits from atezolizumab.
Article
Oncology
Shigeki Yano, Tomokazu Kawaoka, Shintaro Yamasaki, Yusuke Johira, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Yuji Teraoka, Hirotaka Kouno, Shintaro Takaki, Nami Mori, Keiji Tsuji, Shiro Oka
Summary: A total of 137 HCC patients treated with atezolizumab plus bevacizumab were enrolled in this study. The results showed that lenvatinib is an effective treatment option, as it can prolong the overall survival and progression-free survival of patients. Adverse events were relatively common, but none directly caused death.